Viva Biotech buys back 3.50 million shares on 25 June; month-to-date repurchases climb to 9.49 million

Bulletin Express06-25 18:28

Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired within a price range of HKD 1.04–1.10, with a volume-weighted average cost of HKD 1.06 per share, bringing the aggregate consideration for the day to HKD 3.72 million.

Including the latest transaction, shares repurchased between 8 and 25 June 2026 but not yet cancelled total 9.49 million, equivalent to approximately 0.45% of the company’s 2.10 billion issued shares. All repurchased shares are earmarked for cancellation; no treasury shares are being held.

The buybacks are executed under the share repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. As of 25 June 2026, cumulative purchases under this mandate amount to 34.80 million shares, representing 1.64% of the issued share capital on the date the mandate was granted.

Under Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 25 July 2026 following the latest on-market repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185215760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185215760","market":"hk","top_or_hot":-1,"title":"Viva Biotech buys back 3.50 million shares on 25 June; month-to-date repurchases climb to 9.49 million","media":"Bulletin Express","content":"<p>Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired within a price range of HKD 1.04–1.10, with a volume-weighted average cost of HKD 1.06 per share, bringing the aggregate consideration for the day to HKD 3.72 million.</p>\n<p>Including the latest transaction, shares repurchased between 8 and 25 June 2026 but not yet cancelled total 9.49 million, equivalent to approximately 0.45% of the company’s 2.10 billion issued shares. All repurchased shares are earmarked for cancellation; no treasury shares are being held.</p>\n<p>The buybacks are executed under the share repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. As of 25 June 2026, cumulative purchases under this mandate amount to 34.80 million shares, representing 1.64% of the issued share capital on the date the mandate was granted.</p>\n<p>Under Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 25 July 2026 following the latest on-market repurchase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech buys back 3.50 million shares on 25 June; month-to-date repurchases climb to 9.49 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech buys back 3.50 million shares on 25 June; month-to-date repurchases climb to 9.49 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-25 18:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired within a price range of HKD 1.04–1.10, with a volume-weighted average cost of HKD 1.06 per share, bringing the aggregate consideration for the day to HKD 3.72 million.</p>\n<p>Including the latest transaction, shares repurchased between 8 and 25 June 2026 but not yet cancelled total 9.49 million, equivalent to approximately 0.45% of the company’s 2.10 billion issued shares. All repurchased shares are earmarked for cancellation; no treasury shares are being held.</p>\n<p>The buybacks are executed under the share repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. As of 25 June 2026, cumulative purchases under this mandate amount to 34.80 million shares, representing 1.64% of the issued share capital on the date the mandate was granted.</p>\n<p>Under Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 25 July 2026 following the latest on-market repurchase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1185215760","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185215760","pubTimestamp":1782383330,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物于6月25日回购350万股；本月迄今回购量攀升至949万","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings (Viva Biotech) filed a Next Day Disclosure Return showing that 3.50 million ordinary shares were repurchased on 25 June 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired within a price range of HKD 1.04–1.10, with a volume-weighted average cost of HKD 1.06 per share, bringing the aggregate consideration for the day to HKD 3.72 million.\nIncluding the latest transaction, shares repurchased between 8 and 25 June 2026 but not yet cancelled total 9.49 million, equivalent to approximately 0.45% of the company’s 2.10 billion issued shares. All repurchased shares are earmarked for cancellation; no treasury shares are being held.\nThe buybacks are executed under the share repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. As of 25 June 2026, cumulative purchases under this mandate amount to 34.80 million shares, representing 1.64% of the issued share capital on the date the mandate was granted.\nUnder Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 25 July 2026 following the latest on-market repurchase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185215760","isCrawlerRequest":true}